Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial

Journal of Clinical Psychiatry

Volumn 72, Issue 10, 2011, Pages 1313-1321

  Allen, Michael H ^a   Feifel, David ^b   Lesem, Michael D ^e   Zimbroff, Daniel L ^c   Ross, Ruth ^f   Munzar, Patrik ^d,g   Spyker, Daniel A ^d   Cassella, James V ^d  

^a UNIVERSITY OF COLORADO   (United States)

^b UCSD MEDICAL CENTER   (United States)

^c Pacific Clinical Research Medical Group   (United States)

^d Alexza Pharmaceuticals   (United States)

^e Claghorn Lesem Research Clinic Ltd   (United States)

^f Ross Editorial   (United States)

^g STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOXAPINE; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; THROAT IRRITATION; XEROSTOMIA;

EID: 79958061760     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10m06011yel     Document Type: Article

References (43)

1. Osser DN, Sigadel R. Short-term inpatient pharmacotherapy of schizophrenia. Harv Rev Psychiatry. 2001;9(3):89-104.doi:10.1080/1067320127892 PubMed (Pubitemid 32372934)
2. Conn DK, Lieff S. Diagnosing and managing delirium in the elderly. Can Fam Physician. 2001;47:101-108. PubMed (Pubitemid 32182628)
3. Alderfer BS, Allen MH. Treatment of agitation in bipolar disorder across the life cycle. J Clin Psychiatry. 2003;64(suppl 4):3-9. PubMed (Pubitemid 36418557)
4. Battaglia J. Pharmacological management of acute agitation. Drugs. 2005; 65(9):1207-1222.doi:10.2165/03495-20565090-03 PubMed (Pubitemid 41032047)
5. Buckley PF. The role of typical and atypical antipsychotic medications in the management of agitation and aggression. J Clin Psychiatry. 1999; 60(suppl 10):52-60. PubMed (Pubitemid 29237176)
6. Allen MH, Currier GW, Grogg A. Use of restraints and pharmacotherapy in academic psychiatric emergency services. Gen Hosp Psychiatry. 2004; 26(1):42-49.doi:10.1016/j.genhospsych.203.08.02 PubMed (Pubitemid 38142566)
7. Allen MH, Currier GW, Carpenter D, et al. Expert Consensus Guideline Series: Treatment of Behavioral Emergencies. J Psychiatr Pract. 2005; 11(supp 1):1-108. PubMed
8. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry. 2001;62(3): 153-157. PubMed (Pubitemid 32270087)
9. Currier GW, Trenton A. Pharmacological treatment of psychotic agitation. CNS Drugs. 2002;16(4):219-228.doi:10.2165/023210-20216040-02 PubMed (Pubitemid 34492930)
10. Currier GW, Allen MH, Bunney EB, et al. Standard therapies for acute agitation. J Emerg Med. 2004;27(Suppl):S9-S12, quiz S7.doi:10.1016/j.jemermed. 204.09.01 PubMed
11. Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J. 2003;20(4):339-346.doi:10.136/emj.20.4.39 PubMed (Pubitemid 36873910)
12. Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry. 2001;158(7):1149-1151.doi:10.176/api.ajp.158.7.149 PubMed (Pubitemid 32623122)
13. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59(5):441-448.doi:10.101/archpsyc.59.5.41 PubMed (Pubitemid 34477680)
14. Zimbroff DL, Allen MH, Battaglia J, et al. Best clinical practice with ziprasidone IM: update after 2 years of experience. CNS Spectr. 2005; 10(9):1-15. PubMed (Pubitemid 41443046)
15. Preskorn SH. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. Clin Pharmacokinet. 2005;44(11):1117-1133.doi:10.2165/0308-205410- 02 PubMed (Pubitemid 41483699)
16. Abilify [package insert]. Tokyo, Japan: Otsuka Pharmaceuticals; 2008. http://packageinserts.bms.com/pi/pi-abilify.pdf. Accessed August 13, 2010.
17. Allen MH, Currier GW, Hughes DH, et al. Treatment of behavioral emergencies: a summary of the expert consensus guidelines. J Psychiatr Pract. 2003;9(1):16-38.doi:10.1097/0131746-203010-04 PubMed (Pubitemid 36717620)
18. Brice JH, Pirrallo RG, Racht E, et al. Management of the violent patient. Prehosp Emerg Care. 2003;7(1):48-55.doi:10.1080/10903120390937085 PubMed (Pubitemid 36091797)
19. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs. 2002;62(11):1649-1671.doi:10.2165/03495- 2026210-06 PubMed (Pubitemid 34848372)
20. Allen MH, Carpenter D, Sheets JL, et al. What do consumers say they want and need during a psychiatric emergency? J Psychiatr Pract. 2003; 9(1):39-58.doi:10.1097/0131746-203010-05 PubMed (Pubitemid 36717621)
21. Allen MH, Currier GW, Hughes DH, et al. Expert Consensus Panel for Behavioral Emergencies. The Expert Consensus Guideline Series: Treatment of Behavioral Emergencies. Postgrad Med. 2001;(spec no):1-88. PubMed
22. Heel RC, Brogden RN, Speight TM, et al. Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent. Drugs. 1978;15(3):198-217.doi:10.2165/03495-197815030-02 PubMed (Pubitemid 8287432)
23. Glazer WM. Does loxapine have "atypical" properties? clinical evidence. J Clin Psychiatry. 1999;60(suppl 10):42-46. PubMed (Pubitemid 29237174)
24. Paprocki J, Versiani M. A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia. Curr Ther Res Clin Exp. 1977;21(1):80-100. PubMed (Pubitemid 8021606)
25. Fruensgaard K, Korsgaard S, Jorgensen H, et al. Loxapine versus haloperidol parenterally in acute psychosis with agitation: a double-blind study. Acta Psychiatr Scand. 1977;56(4):256-264.doi:10.1/j.160-047.197.tb026.x PubMed (Pubitemid 8190608)
26. Dubin WR, Weiss KJ. Rapid tranquilization: a comparison of thiothixene with loxapine. J Clin Psychiatry. 1986;47(6):294-297. PubMed (Pubitemid 16062284)
27. Gaussares C, Gerard H, Bosc M. Interest in injectable loxapine for severe agitation. Inf Psychiatr. 1989;69:656-660.
28. Bourdinaud V, Pochard F. Survey of management methods for patients in a state of agitation at admission and emergency departments in France. Encephale. 2003;29(2):89-98. PubMed (Pubitemid 36565979)
29. Spyker DA, Munzar P, Cassella JV. Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol. 2010;50(2):169-179. PubMed
30. Cooper TB, Kelly RG. GLC analysis of loxapine, amoxapine, and their metabolites in serum and urine. J Pharm Sci. 1979;68(2):216-219.doi:10.102/jps. 26068024 PubMed (Pubitemid 9117129)
31. Midha KK, Hubbard JW, McKay G, et al. The role of metabolites in a bioequivalence study 1: loxapine, 7-hydroxyloxapine and 8-hydroxyloxapine. Int J Clin Pharmacol Ther Toxicol. 1993;31(4): 177-183. PubMed (Pubitemid 23108060)
32. Simpson GM, Cooper TB, Lee JH, et al. Clinical and plasma level characteristics of intramuscular and oral loxapine. Psychopharmacology (Berl). 1978;56(2):225-232.doi:10.107/BF043185 PubMed (Pubitemid 8287712)
33. Wolpert A, White L, Dana L, et al. Clinical pharmacological trial of loxapine succinate. J Clin Pharmacol. 1970;10:175-181.
34. Tuason VB. A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients. J Clin Psychiatry. 1986;47(3):126-129. PubMed (Pubitemid 16166353)
35. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale Manual. North Tonawanda, NY: Multi-Health Systems; 1994.
36. FDA Psychopharmacology Advisory Committee. Briefing Document for Zyprexa IntraMuscular (olanzapine for injection). http://www.fda.gov/ ohrms/dockets/ac/01/briefing/3685b1-01-lilly.pdf. Published February 14, 2001. Accessed November 20, 2010.
37. Rabinowitz JD, Wensley M, Lloyd P, et al. Fast onset medications through thermally generated aerosols. J Pharmacol Exp Ther. 2004; 309(2):769-775.doi:10. 124/jpet.103.062893 PubMed (Pubitemid 38542633)
38. Rabinowitz JD, Lloyd PM, Munzar P, et al. Ultra-fast absorption of amorphous pure drug aerosols via deep lung inhalation. J Pharm Sci. 2006;95(11):2438-2451.doi:10.102/jps.20694 PubMed (Pubitemid 44726384)
39. Kay SR, Sevy S. Pyramidical model of schizophrenia. Schizophr Bull. 1990;16(3):537-545. PubMed
40. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised. Rockville, MD: Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976:218-222.
41. Swift RH, Harrigan EP, Cappelleri JC, et al. Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients. J Psychiatr Res. 2002;36(2):87-95.doi:10.1016/S02-3956(01) 052-8 PubMed (Pubitemid 34007608)
42. Poyurovsky M, Nave R, Epstein R, et al. Actigraphic monitoring (actigraphy) of circadian locomotor activity in schizophrenic patients with acute neuroleptic-induced akathisia. Eur Neuropsychopharmacol. 2000;10(3):171-176.doi:10.1016/S0924-97X(0)063-8 PubMed
43. Cassella J, Spyker D, Fishman R. Inhaled loxapine is an effective and rapid treatment for agitation in schizophrenic patients. The International Congress on Schizophrenia Research; March 28-April 1, 2009; San Diego, CA.